Cancer risk increases with age and is often more aggressive and difficult to treat in older adults. However, fewer than 10% of mouse studies use aged animals, with most relying on mice roughly ...

Fred Hutch Cancer Center molecular biologist Dr. Kevin Barry just received a $270,000, two-year grant from the American ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

A closely watched clinical trial testing a new two-drug combination against metastatic uveal melanoma, the deadliest form of ...

Famed ESPN broadcaster Dick Vitale is facing another battle with cancer. Vitale said Monday that biopsy results had confirmed ...

Servier $210 million bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as the drug has hit the mark in a phase 2/3 that could form the basis of regulatory filings later this ...

IDEAYA Biosciences (IDYA) stock jumped 26% after its eye cancer drug combo doubled progression-free survival in a Phase 2/3 trial versus standard care.

IDEAYA Biosciences Inc. IDYA shares are up during Monday’s premarket session following the announcement of positive topline results from the Phase 2/3 trial for darovasertib in combination with ...

A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...

IDEAYA Biosciences and French pharma company Servier said ​on Monday their combination drug for a type of eye cancer met the ‌main goal of a mid-to-late-stage trial, sending the U.S. biotech's shares ...

How Merck keeps the price of its lifesaving cancer drug, Keytruda, sky-high, locking out patients and squeezing health care ...